Afdelinger Se de enkelte afdelingers forskningsprofil
Rigshospitalet
Bone Status in Obese, Non-diabetic, Anti...
Rigshospitalet - en del af Københavns Universitetshospital
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
https://doi.org/10.3389/fpsyt.2018.00781
Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers
Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes
Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study
Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors
Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men
Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study
Robert Eriksson
Brian V Broberg
Pelle L Ishøy
Nikolaj Bak
Ulrik B Andersen
Niklas R Jørgensen
Filip K Knop
Bjørn H Ebdrup
Klinik for Klinisk Fysiologi, Nuklearmedicin og PET, Diagnostisk Center Rigshospitalet
Klinisk Biokemisk Afdeling , Diagnostisk Center Rigshospitalet
Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial (n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 mg once-weekly (n = 23), or placebo (n = 22) on bone turnover markers (BTMs) and BMD in chronic, obese, antipsychotic-treated patients with schizophrenia spectrum disorder. Baseline BTMs were compared to sex- and age-adjusted reference values from a Danish population cohort, and T- and Z-scores were calculated for BMD. Results: In women (n = 24), all baseline BTM measurements of procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX) were within reference values. In men (n = 21), 5% displayed lower PINP and 14% displayed lower CTX. One patient displayed BMD Z-score < -2, and 23% of patients (17% of women and 29% of men) displayed -2.5 < T-scores < -1 indicating osteopenia, but none had osteoporosis. After treatment, PINP decreased at trend level significance (P = 0.05), and body mass index BMD increased for L2-L4 (P = 0.016). No changes in bone markers were significant after correction for mean prolactin levels. Conclusions: Sex- and age-adjusted measures of bone status in chronic, obese, antipsychotic-treated patients appeared comparable to the reference population. Subtle changes in bone markers during 3 months exenatide treatment may suggest beneficial effects of GLP-1 receptor agonists on bone status in antipsychotic-treated patients, and further studies should consider the potential influence of prolactin.
Udgivet - 28 jan. 2019
Blegdamsvej 9